Printed from Voxsanity (voxsanity.com.au) — NCT07704190 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Phase 4 Type 2 Diabetes Trial, Not Yet Recruiting
NCT07704190
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older at the time of screening.
- People who have at least one of the following metabolic conditions: a body mass index (a measure of body weight relative to height) of 23 or above; a waist measurement of 80 cm or more (for women) or 90 cm or more (for men); a fasting blood sugar or average blood sugar level in a range that suggests pre-diabetes; high triglycerides (a type of fat in the blood) above a certain level; or a documented history of high blood pressure, metabolic syndrome, or diabetes.
- People who meet at least one of the following signs of chronic kidney disease: kidney filtering function (measured by a blood test called eGFR) between 15 and below 60; or a high level of a protein called albumin in the urine (above a certain threshold) with relatively preserved kidney filtering function and a documented history of this protein being in the urine.
- People who have documented cardiovascular disease caused by hardening or narrowing of the arteries, in at least one of these forms: heart-related — a previous heart attack, a procedure to open or bypass blocked heart arteries, or a confirmed significant narrowing (50% or more) of a major heart artery; brain-related — a previous stroke caused by artery disease, a procedure on the carotid artery in the neck, or confirmed significant narrowing of a carotid artery; or narrowing of arteries in the legs or other limbs causing symptoms.
- People who are willing and able to sign a written consent form to take part in the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have signs of an active infection, or where the study doctor suspects one may be present.
- People who have had a heart attack, stroke, a brief stroke-like episode (TIA), or a hospital stay for severe chest pain within the 60 days before joining the study.
- People who have a planned procedure to open or bypass blocked arteries (in the heart, neck, or limbs) at the time of joining the study.
- People who have had major heart surgery, major non-heart surgery, or a major internal camera procedure within the 60 days before joining, or who have such a procedure planned during the study.
- People currently taking medicines that suppress the immune system, such as steroids, certain targeted therapies, biologic medicines used for immune conditions, or anti-cancer drugs.
- People who are on long-term regular kidney dialysis (either hemodialysis or peritoneal dialysis).
- People with a current or past history of active tuberculosis (TB).
- People with a history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).
- People who have had an active cancer or early-stage cancer (carcinoma in situ) within the past five years.
- People with very high blood pressure that is not controlled (top number above 180 mmHg or bottom number above 110 mmHg).
- People with severe heart failure classified as the most serious category (NYHA Class IV), meaning significant symptoms even at rest.
- People who have had a bone marrow or organ transplant in the past, or who have a transplant planned during the study period.
- People with a known or suspected allergy to the study drug (secukinumab) or any of its ingredients.
- People who are pregnant, breastfeeding, or who are capable of becoming pregnant and are not using an adequate form of contraception.
- People whose blood test results show low levels of certain white blood cells or platelets, or elevated liver enzyme levels above a certain threshold.
- People whose long-term average blood sugar level (HbA1c) is 10% or above, indicating poorly controlled diabetes.
- People with any other health condition that the study doctor believes could put them at risk or make it difficult to follow the study requirements.
- People who, in the study doctor's judgment, are not receiving an adequate standard level of treatment for their condition.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
Contact this trial
Phone: +86 13911292690
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
15 July 2026
Est. completion
31 December 2028
Primary endpoints
Time to First Occurrence of 3-point Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.